Tetra Bio-Pharma Inc. (JAM1.F)
Chart Events
Performance Outlook
| Previous Close | 0.0309 |
| Open | 0.0308 |
| Bid | 0.0310 x 4074100 |
| Ask | 0.0597 x 2558200 |
| Day's Range | 0.0345 - 0.0345 |
| 52 Week Range | 0.0300 - 0.2755 |
| Volume | |
| Avg. Volume | 353 |
| Market Cap | 20.552M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0810 |
| Earnings Date | Apr 13, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for JAM1.F
Related Research
- CNW Group
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.
- PR Newswire
Tetra Bio-Pharma and Cannvalate Enter Into Partnership
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development, today announced it has entered into a research and development agreement with Cannvalate Pty Ltd ("Cannvalate") for the initiation of the REBORN®, PLENITUDE® and CAUMZ® clinical trials in Australia, and a subscription agreement contemplating a private placement (the "Private Placement") of common shares in the capital of the Company (the "Common Sh
- CNW Group
Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for its inhaled cannabinoid-based product, QIXLEEF™. The meeting was held to discuss the nonclinical safety requirements for the marketing approval.
